Marker Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures Powers of Attorney (included on signature page)
SIGNATURES
Pursuant to the requirements of Section 13 and 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: March 18, 2026
| | Marker Therapeutics, Inc. | |
|---|---|---|
| By: | /s/ Juan Vera | |
| Juan Vera | ||
| President, Chief Executive Officer and Treasurer (Principal Executive Officer and Principal Financial and Accounting Officer) | ||
POWER OF ATTORNEY
Each of the undersigned officers and directors of Marker Therapeutics, Inc., hereby constitutes and appoints Juan Vera their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on March 28, 2026 on behalf of the registrant and in the capacities indicated.
| Signature | | Title | | Date | |
|---|---|---|---|---|---|
| /s/ Juan Vera | | President, Chief Executive Officer and Treasurer, Director (Principal Executive Officer and Principal Financial and Accounting Officer) | | March 18, 2026 | |
| Juan Vera | | | | | |
| | | | | | |
| /s/ N. David Eansor | | Chairman | | March 18, 2026 | |
| N. David Eansor | | | | | |
| | | | | | |
| /s/ Katharine Knobil | | Director | | March 18, 2026 | |
| Katharine Knobil | | | | | |
| | | | | | |
| /s/ Steve Elms | | Director | | March 18, 2026 | |
| Steve Elms | | | | | |
| | | | | | |
| /s/ Kathryn Penkus Corzo | | Director | | March 18, 2026 | |
| Kathryn Penkus Corzo | | | | | |
CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2025 AND DECEMBER 31, 2024
| | | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 688) | | F-2 |
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 199) | | F-4 |
| Consolidated Balance Sheets | | F-6 |
| Consolidated Statements of Operations | | F-7 |
| Consolidated Statements of Stockholders’ Equity | | F-8 |
| Consolidated Statements of Cash Flows | | F-9 |
| Notes to the Consolidated Financial Statements | | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.